Influenza may do more than cause a week of fever and fatigue
New research from Imperial College London suggests an influenza infection can weaken the body’s ability to control the bacterium that causes tuberculosis, adding evidence that common viral infections may shape the course of one of the world’s deadliest infectious diseases.
The study, published in Nature Communications, used blood samples from Imperial’s human challenge studies program, in which healthy volunteers are infected with influenza under controlled conditions and monitored closely. Researchers reported that after flu infection, immune pathways involved in controlling the growth of Mycobacterium tuberculosis were inhibited.
That matters because tuberculosis remains a major global health burden. The researchers note that around 11 million people fall ill with TB each year, and the disease remains one of the leading infectious killers worldwide. A finding that a seasonal respiratory virus can weaken anti-TB defenses raises new questions for countries where both infections circulate heavily.
Why the result stands out
Respiratory infections have long been suspected of interacting with tuberculosis, but establishing direct evidence in humans is difficult. Imperial’s challenge-study framework gave the team a controlled way to track what happens to immune signaling after flu infection, rather than inferring those effects from observational data alone.
Lead author Dr. Claire Broderick said the work provides direct evidence in humans that influenza impairs the body’s ability to control the growth of the bacteria responsible for TB. The team said the study also helped identify specific immune pathways that are disrupted by influenza, offering a clearer biological explanation for the interaction.
The broader implication is straightforward: if flu can transiently reduce the body’s ability to contain TB bacteria, then seasonal influenza may contribute to tuberculosis risk in populations already vulnerable because of exposure, crowding, or limited access to care.
Could flu vaccines have a second benefit?
One of the most consequential suggestions in the paper is that seasonal influenza vaccination could have value beyond preventing influenza itself. The researchers say flu vaccines might offer a new strategy for helping prevent or control tuberculosis in regions with high TB prevalence, including countries such as India, Indonesia, and South Africa.
That is not the same as saying a flu shot is a TB vaccine. The study does not claim that influenza vaccination directly prevents tuberculosis infection. Instead, the argument is narrower and still important: reducing flu infections could preserve immune function that helps keep TB bacteria in check.
For public health planners, that possibility could eventually strengthen the case for broader influenza vaccine uptake in places where TB control remains difficult. It may also shape how health officials think about infection seasons, vaccination campaigns, and co-circulating disease burdens.
What the study actually tested
The work relied on blood samples and immune analyses from volunteers infected with influenza in a supervised research setting. Human challenge studies are designed to let scientists observe the onset and early development of infection under controlled conditions. In this case, that approach made it possible to test how influenza altered immune pathways linked to TB control.
The article does not present the study as evidence that every flu infection will lead to tuberculosis, nor does it suggest the effect is the only factor in TB progression. Tuberculosis risk depends on many variables, including exposure history, underlying health, living conditions, and access to diagnosis and treatment.
Still, identifying a measurable immunological effect in humans gives the field something more concrete than theory. It suggests flu infection is not just a parallel health problem in TB-endemic regions, but potentially part of the disease ecology that shapes outcomes.
Why coinfections matter more than ever
Modern medicine often treats infectious diseases in separate lanes: one program for influenza, another for tuberculosis, another for vaccination. Studies like this one push against that siloed view. They show how one infection can alter host defenses in ways that matter for another, changing the practical value of prevention tools already in use.
For health systems under pressure, that kind of overlap can be significant. If preventing influenza also reduces some downstream vulnerability to tuberculosis, then existing flu vaccination infrastructure may have underappreciated value. That could be especially relevant in settings where TB remains entrenched and every marginal gain in prevention matters.
The findings also underscore the strategic value of challenge studies. By safely generating detailed immune data in controlled conditions, they can reveal interactions that are hard to isolate in the real world, where timing, exposures, and patient histories vary widely.
What comes next
The immediate next step will be to confirm how these immune disruptions translate into real-world TB risk and whether vaccination campaigns measurably affect outcomes in high-burden areas. Researchers will also want to understand how long the influenza-related immune changes persist and whether they differ across age groups or prior exposure histories.
Even at this early stage, the study adds a useful layer to global infectious-disease strategy. Influenza is often framed as seasonal and routine; tuberculosis is chronic, entrenched, and deadly. This research suggests the two may be linked more closely than many public health models have assumed.
If that link holds up, a familiar intervention such as a seasonal flu vaccine could end up playing a broader role in global disease control than previously recognized.
This article is based on reporting by Medical Xpress. Read the original article.
Originally published on medicalxpress.com
